Abstract
Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Current Enzyme Inhibition
Title: Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Volume: 2 Issue: 1
Author(s): John D. Imig and Xueying Zhao
Affiliation:
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Abstract: Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Export Options
About this article
Cite this article as:
Imig D. John and Zhao Xueying, Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease, Current Enzyme Inhibition 2006; 2 (1) . https://dx.doi.org/10.2174/157340806775473544
DOI https://dx.doi.org/10.2174/157340806775473544 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Achieving Better Blood Pressure Control in High-Risk Patients with Type 2 Diabetes Using Combination Antihypertensive Therapy
Vascular Disease Prevention (Discontinued) Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients
Current Neurovascular Research Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Molecular Genetic Approaches for Studying the Etiology of Diabetic Nephropathy
Current Molecular Medicine Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry